New smoking cessation pill shows promise in large trial

NCT ID NCT05206370

First seen Jan 15, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This study tested a pill called cytisinicline in 792 adult smokers who wanted to quit. Participants took the pill or a placebo for either 6 or 12 weeks. The main goal was to see if the pill helped them stop smoking, confirmed by breath tests. The results could offer a new option for people trying to quit smoking.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOKING CESSATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Accel Research Sites - DeLand Clinical Research Unit

    DeLand, Florida, 32720, United States

  • Affinity Health Corp

    Oak Brook, Illinois, 60523, United States

  • Alliance for Multispecialty Research, LLC

    Fort Myers, Florida, 33912, United States

  • Aventiv Research Inc

    Columbus, Ohio, 43212, United States

  • Clinical Research Associates, Inc.

    Nashville, Tennessee, 37203, United States

  • Global Medical Institutes LLC; Princeton Medical Institute

    Princeton, New Jersey, 08540, United States

  • Health Research of Hampton Toads, Inc

    Newport News, Virginia, 23606, United States

  • Intend Research

    Norman, Oklahoma, 73069, United States

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216, United States

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana, 47714, United States

  • Trial Management Associates, LLC

    Wilmington, North Carolina, 28403, United States

  • Velocity Clinical Research, Inc.

    Cleveland, Ohio, 44122, United States

Conditions

Explore the condition pages connected to this study.